In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and
biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through …

Critical driver genomic events in colorectal cancer have been shown to affect the response
to targeted agents that were initially developed under the'one gene, one drug'paradigm of …

Immunotherapy for metastatic colorectal cancer is effective only for mismatch repair-deficient
tumors with high microsatellite instability that demonstrate immune infiltration, suggesting …

Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and
drug responses. To resolve inconsistencies among the reported gene expression–based …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Colon cancer is the third most common cancer worldwide. Most colorectal cancer
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …

Colorectal cancer (CRC) shows variable underlying molecular changes with two major
mechanisms of genetic instability: chromosomal instability and microsatellite instability. This …

Colorectal cancer (CRC) is a major cause of cancer mortality. Whereas some patients
respond well to therapy, others do not, and thus more precise, individualized treatment …

Stromal content heavily impacts the transcriptional classification of colorectal cancer (CRC),
with clinical and biological implications. Lineage-dependent stromal transcriptional …

The recognition that colorectal cancer (CRC) is a heterogeneous disease in terms of clinical
behaviour and response to therapy translates into an urgent need for robust molecular …